devices as"integrated" CGM sensors. This means that they can now be used as components in automated insulin delivery systems, along with insulin pumps and connectivity software.
The modified FreeStyle Libre 2 and FreeStyle Libre 3 sensors have been cleared for use by patients as young as age 2 years and for up to 15 days, in contrast to the previous versions, which were available for patients as young as 4 years for use up to 14 days. The FDA has cleared all Libre sensors ― 2 and 3, current and future versions ― for use by pregnant women with any type of diabetes.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: